Findings on the role of VEGF in neo-angiogenesis have made it a key therapeutic target for anti-cancer strategies and has led to the design of monoclonal antibodies or multi-kinase inhibitors targeting VEGF-alpha or its cognate endothelial receptor tyrosine kinases, VEGFR1, 2, and 3. This evidence concerns the gene VEGFA and cancer.